Unknown

Dataset Information

0

Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.

ABSTRACT: The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation refractory to conservative treatment.This study is an open-label, multicenter randomized controlled trial. Patients aged 14 to 80 with slow-transit constipation, a defecation frequency (DF)

SUBMITTER: Heemskerk SCM 

PROVIDER: S-EPMC5859034 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis.

Heemskerk S C M SCM   Rotteveel A H AH   Benninga M A MA   Baeten C I M CIM   Masclee A A M AAM   Melenhorst J J   van Kuijk S M J SMJ   Dirksen C D CD   Breukink S O SO  

International journal of colorectal disease 20180222 4

<h4>Purpose</h4>The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation r  ...[more]

Similar Datasets

Unknown Efficacy of Synbiotics in Patients with Slow Transit Constipation: A Prospective Randomized Trial.
| S-EPMC5083993 | biostudies-literature
Unknown Fecal microbiota transplantation in patients with slow-transit constipation: A randomized, clinical trial.
| S-EPMC5291446 | biostudies-literature
Unknown Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation.
| S-EPMC3813955 | biostudies-literature
Unknown Colonic Transit Time and Gut Peptides in Adult Patients with Slow and Normal Colonic Transit Constipation.
| S-EPMC5610809 | biostudies-literature
Unknown Gut Microbiota Alterations from Three-Strain Yogurt Formulation Treatments in Slow-Transit Constipation.
| S-EPMC7049856 | biostudies-literature
Unknown Astragaloside IV improves slow transit constipation by regulating gut microbiota and enterochromaffin cells.
| S-EPMC10703044 | biostudies-literature
Unknown Success and Complication Rates After Sacral Neuromodulation for Fecal Incontinence and Constipation: A Single-center Follow-up Study.
| S-EPMC6326196 | biostudies-literature
Unknown Slow-transit constipation and criteria for colectomy: a cross-sectional study of 1568 patients.
| S-EPMC8164778 | biostudies-literature
Unknown Comparative Transcriptome Analysis Reveals Relationship among mRNAs, lncRNAs, and circRNAs of Slow Transit Constipation.
| S-EPMC8427675 | biostudies-literature
Unknown Characterization of Patients With Obstructed Defecation and Slow Transit Constipation With a Simulated Stool.
| S-EPMC8099406 | biostudies-literature